ASX:CSLBiotechs
CSL (ASX:CSL) Following ANDEMBRY Trial Results Still Looks Cheap Against Fair Value
CSL (ASX:CSL) has drawn fresh attention after reporting positive top-line Phase 3b results for its hereditary angioedema therapy ANDEMBRY in children aged 2 to 11 years, supporting potential expanded pediatric use.
See our latest analysis for CSL.
The ANDEMBRY update comes as CSL trades at A$123.06, with a 7 day share price return of 7.74% and a year to date share price decline of 28.44%. The 1 year total shareholder return is down 52.25%, pointing to weak long term momentum despite a recent...